DYN - NASDAQ
Dyne Therapeutics, Inc.
$17.99
-3.4%Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was incorporated in 2017 and is headquartered in Waltham, Massachusetts..
At a Glance
Live SnapshotDyne Therapeutics, Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Strong cash conversion. Most reported earnings translate into actual cash flow, suggesting solid fundamentals.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.
Working Capital Impact
Minimal working capital impact on FCF. Changes in operating assets and liabilities well-managed.
Cash Flow Quality Insight
Working capital strain: Significant cash tied up in operations. Monitor receivables collection, inventory turns, and payment terms to optimize cash conversion cycle.
Dyne Therapeutics, Inc. Cash Flow Statement
DYN • NASDAQ
| Dyne Therapeutics, Inc. Cash Flow Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | Dec 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
OPERATING ACTIVITIES | |||||||||||||||||||
-446.2M | -317.4M | -235.9M | -168.1M | -149.3M | -59.4M | -14.9M | -4.8M | 76M | -1.2B | 50M | -67M | -356M | 87M | -1.6B | -234M | -1.3B | 174M | 264M | |
2M | -1.9M | 1.7M | 1.7M | 1.1M | 700K | 271K | 24K | 867M | 766M | 614M | 292M | 467M | 26M | 346M | 408M | 359M | 376M | 333M | |
0.0 | 0.0 | 0.0 | 0.0 | 2.6M | 12K | 0.0 | 0.0 | 610M | 45M | 477M | 1M | 56M | 0.0 | 632M | 195M | -436M | 73M | 215M | |
45.9M | 45.9M | 20M | 15.2M | 17.5M | 6.6M | 26K | 1K | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
-1.5M | 607K | -173K | 3M | -746K | 514K | 1.3M | 21K | 584M | 136M | -215M | -1.3B | -275M | -340M | 813M | -434M | 2.4B | -741M | -471M | |
-3.4M | -19.5M | 26.3M | -5.4M | 9.3M | 5.1M | 1.4M | 601K | -1.6B | 938M | -860M | 1B | 268M | 183M | -166M | 488M | -910M | 437M | 522M | |
-403.2M | -292.4M | -188.2M | -153.6M | -119.6M | -46.5M | -11.8M | -4.2M | 585M | 676M | 94M | -62M | 175M | -44M | -20M | 423M | 135M | 319M | 341M | |
INVESTING ACTIVITIES | |||||||||||||||||||
-1.9M | -2.4M | -729K | -3.1M | -3.6M | -1.2M | -1.6M | -134K | -224M | -326M | -275M | (0.0) | -98M | (0.0) | -242M | -333M | (0.0) | (0.0) | (0.0) | |
(0.0) | (0.0) | (0.0) | (34K) | (8K) | (0.0) | (0.0) | (0.0) | -3.3B | (0.0) | -6.1B | (0.0) | (234M) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | -128M | |
-180.5M | -317.4M | -44.3M | -121.2M | -236.7M | -44.5M | (0.0) | (0.0) | (0.0) | (0.0) | -250M | (0.0) | (0.0) | (0.0) | (0.0) | -508M | (0.0) | (0.0) | (0.0) | |
172.5M | 115.7M | 128.3M | 211.4M | 102.4M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
-18.8M | 35K | 0.0 | -34K | -8K | 0.0 | 0.0 | 0.0 | 784M | -1.8B | 5.4B | -5.1B | 338M | 348M | -12M | 307M | 251M | -102M | -689M | |
-28.8M | -204.1M | (83.3M) | (87.2M) | -137.9M | -45.7M | -1.6M | -134K | -2.8B | -2.1B | -1.2B | -5.1B | (474M) | (348M) | -254M | -534M | (251M) | -102M | -817M | |
FINANCING ACTIVITIES | |||||||||||||||||||
742.6M | 773.1M | 52.4M | 36.9M | 157.2M | 246.4M | 0.0 | 7K | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
147.7M | 0.0 | 0.0 | 0.0 | 0.0 | -64K | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | -250M | -1.9B | -843M | -348M | -396M | -291M | (0.0) | (0.0) | (0.0) | |
0.0 | 36.8M | 2M | 529K | 584K | -420K | 0.0 | 5M | -1.3B | 2.7B | -265M | 5.2B | -154M | -328M | 379M | -69M | -608M | 148M | 433M | |
890.3M | 809.9M | 54.3M | 37.4M | 157.8M | 380.7M | 20M | 12.4M | -1.3B | 2.7B | -265M | 5.2B | -154M | -328M | 379M | -69M | -608M | 148M | 433M | |
CASH FLOW SUMMARY | |||||||||||||||||||
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 4.3M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -83M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
458.3M | 313.5M | -50.5M | -29.1M | -99.6M | 288.5M | 6.5M | 12.4M | -3.5B | 1.3B | -1.4B | 0.0 | 495M | -107M | 105M | -180M | -222M | 365M | -43M | |
437.4M | 123.9M | 174.5M | 203.5M | 303.2M | 14.6M | 8.1M | -4.3M | 3.8B | 505M | 1.9B | 1.9B | 348M | 455M | 291M | 471M | 693M | 328M | 371M | |
895.7M | 437.4M | 123.9M | 174.5M | 203.5M | 303.2M | 14.6M | 8.1M | 365M | 1.8B | 505M | 1.9B | 843M | 348M | 396M | 291M | 471M | 693M | 328M | |
-405.1M | -294.7M | -188.9M | -156.7M | -123.2M | -47.7M | -13.5M | -4.3M | 361M | 350M | -181M | -62M | 77M | -44M | -262M | 90M | 135M | 319M | 341M |
SEC Filings
DYN - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | June 03, 2026 | June 03, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 11, 2026 | May 11, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 11, 2026 | March 31, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 23, 2026 | April 22, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 02, 2026 | March 02, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 02, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | January 12, 2026 | January 12, 2026 | 2026 | |
8-K 8-K 2025 N/A | December 23, 2025 | December 22, 2025 | 2025 | |
8-K 8-K 2025 N/A | December 10, 2025 | December 09, 2025 | 2025 | |
8-K 8-K 2025 N/A | December 08, 2025 | December 08, 2025 | 2025 |
Related Guides
Continue your DYN research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.